Genomic profiling – Collaboration by New Oncology and University Hospital Oslo

0
991

1 2

New Oncology and the University Hospital Oslo are collaborating to identify alterations in cancer-related tumor genes that predict a patient’s response or resistance to targeted therapies. New Oncology will apply its proprietary diagnostic platform ‘NEO’ that provides a fully informative molecular cancer profile from the smallest quantities of patient samples with short turn-around times. New Oncology’s proprietary diagnostic platform ‘NEO’ empowers physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials.

“Dramatic responses to targeted therapies in patients with advanced solid tumours bearing drug-sensitizing mutations have shifted the paradigm of cancer treatment towards a comprehensive molecular characterization before initiation of treatment. The growing number of targeted drugs, different types of targetable genome alterations and the occurrence of resistance mechanisms are increasing challenges for clinical diagnostics. Technological and computational advances in the field of tumour diagnostics finally put us in the position to perform comprehensive, sensitive and fast analysis of all different types of genome alterations on routine tumour specimens. This is a pivotal step in matching the right patients with the right drugs, providing broad access to personalized cancer medicine to all patients” commented Prof. Roman Thomas, founder of New Oncology.

This article is based on materials provided by: http://www.b3cnewswire.com/201501221156/new-oncology-and-university-hospital-oslo-announce-genomic-profiling-collaboration.html

 Disclaimer: This articles does not reflect any personal views of the authors/editors

Previous articleScientists come up with a solution for baldness using stem cells
Next articleVitamin C is beneficial for plants too!
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.